The BIOSECURE Act was passed with a large bipartisan majority in the House in 2024 and now awaits action in the Senate in 2025. Passage of the Act would be a significant first step in protecting ...

Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...

The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

A Chinese pharmaceutical company expects to hire up to 500 employees for the first phase of its new campus in northern ...

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a ...

Aragen, based in Hyderabad, says it will use the funds to boost manufacturing capacity for newer treatment modalities, such as peptides, oligonucleotides, and antibody-drug conjugates (ADCs), and to ...

Pharma Sector Multibagger Opportunity - Explore how India could win big in the CDMO space with China-Plus-One strategy, growing investments, strategic advantages, and the Pharma sector's global shift.

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 ...

The Indian pharmaceutical market sees negative volume growth in Q3FY25 but benefits from strong pricing and new product ...